Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $419.8 million.

  • Axsome Therapeutics' Total Non-Current Liabilities rose 31.14% to $505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.7 million, marking a year-over-year increase of 31.14%. This contributed to the annual value of $419.8 million for FY2024, which is 29.59% up from last year.
  • As of FY2024, Axsome Therapeutics' Total Non-Current Liabilities stood at $419.8 million, which was up 29.59% from $324.0 million recorded in FY2023.
  • Axsome Therapeutics' Total Non-Current Liabilities' 5-year high stood at $419.8 million during FY2024, with a 5-year trough of $190.8 million in FY2022.
  • In the last 3 years, Axsome Therapeutics' Total Non-Current Liabilities had a median value of $324.0 million in 2023 and averaged $311.5 million.
  • Data for Axsome Therapeutics' Total Non-Current Liabilities shows a peak YoY skyrocketed of 69.77% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Total Non-Current Liabilities (Yearly) stood at $190.8 million in 2022, then spiked by 69.77% to $324.0 million in 2023, then increased by 29.59% to $419.8 million in 2024.